Singapore, April 18 -- US-based Wayfinder Biosciences has entered into a collaboration with Japanese pharma firm Daiichi Sankyo to develop RNA-targeting small molecule therapies aimed at treating neurodegenerative diseases.

Wayfinder, a biotechnology company specialising in RNA-targeting technologies, has developed a platform that identifies potent and selective small molecules. These molecules are designed to bind directly to RNA, neutralising the harmful effects of disease-related genes. Unlike traditional drugs that often target proteins, this approach enables access to previously undruggable targets.

The company's proprietary platform integrates RNA-based sensors and a data generation engine to provide scalable, quantitative insight...